Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Long-Term Deferred Tax: 2022-2023

  • Syndax Pharmaceuticals' Long-Term Deferred Tax rose 62.78% to $79.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $79.6 million, marking a year-over-year increase of 62.78%. This contributed to the annual value of $79.6 million for FY2023, which is 62.78% up from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Long-Term Deferred Tax stood at $79.6 million for Q4 2023, which was up 62.78% from $48.9 million recorded in Q4 2022.
  • In the past 5 years, Syndax Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $79.6 million in Q4 2023 and a low of $48.9 million during Q4 2022.
  • Over the past 2 years, Syndax Pharmaceuticals' median Long-Term Deferred Tax value was $64.2 million (recorded in 2022), while the average stood at $64.2 million.
  • Data for Syndax Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY spiked of 62.78% (in 2023) over the last 5 years.
  • Over the past 2 years, Syndax Pharmaceuticals' Long-Term Deferred Tax (Quarterly) stood at $48.9 million in 2022, then skyrocketed by 62.78% to $79.6 million in 2023.